Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline

This is a clinical practice guideline for men with metastatic non-castrate prostate cancer being considered for treatment with androgen-deprivation therapy (ADT). The guideline examines the addition of docetaxel or abiraterone to ADT, and the resulting effects on overall survival (OS), progression-free survival (PFS), failure-free survival (FFS), prostate-specific antigen (PSA) response, overall response rate, and quality of life (QOL).